TrialBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2015

A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial.

John Koreth et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.